Description
TNF-related apoptosis-inducing ligand (TRAIL) is a ligand molecule which induces apoptosis. It is a type II transmembrane protein with homology to other members of the tumor necrosis factor family. In humans, the gene that encodes for TRAIL is located at chromosome 3q26.
TRAIL binds to the death receptors, DR4 and DR5. The process of apoptosis is caspase-8-dependent. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues.
Soluble TNF-related apoptosis-inducing ligand Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 168 amino acids and having a molecular mass of 19.6 kDa.
The sTRAIL is purified by proprietary chromatographic techniques.
2. Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res 2007 Jun 1;67(11):5397-407.
3. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 2007 May;9(5):435-42.
4. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007 May 15;67(10):4981-8.
5. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer Res 2007 May 15;67(10):4973-80.
6. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007 May;8(4):395-403.
Related products
- AITRL Human
- Cardiotrophin 1
- CXCL7/NAP-2
- IL-17
- IL-3 Human
- IL-3 Mouse
- IL-3 Rat
- IL-6
- IL-6, His Tagged
- Macrophage Inflammatory Protein-3 alpha (CCL20)
- Oncostatin-M
- Transferrin
For research use only. Not for diagnostic or clinical use.